Clinical Trial: NCT04489173
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Borstkanker Onderzoek Groep |
| Information Provided By: | Borstkanker Onderzoek Groep |
| Last Update Posted: | 2026-05-22 |
Study Overview
Brief Summary
This is a multicenter phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
Official Title
A Phase 2 Study of Trifluridine/Tipiracil in Patients With ER-positive, HER2-negative Advanced Breast Cancer That Previously Received Chemotherapy
Conditions
Breast Neoplasm, Chemotherapy Effect
Intervention / Treatment
- Drug: trifluridine/tipiracil
Other Study ID Numbers
- BOOG 2019-01
Start Date (Actual)
2020-09-25
Primary Completion Date (Actual)
2024-01-08
Study Completion Date (Actual)
2026-05-19
Enrollment (Actual)
52
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Borstkanker Onderzoek Groep |
| Information Provided By: | Borstkanker Onderzoek Groep |
| Last Update Posted: | 2026-05-22 |
Study Overview
Brief Summary
This is a multicenter phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
Official Title
A Phase 2 Study of Trifluridine/Tipiracil in Patients With ER-positive, HER2-negative Advanced Breast Cancer That Previously Received Chemotherapy
Conditions
Breast Neoplasm, Chemotherapy Effect
Intervention / Treatment
- Drug: trifluridine/tipiracil
Other Study ID Numbers
- BOOG 2019-01
Start Date (Actual)
2020-09-25
Primary Completion Date (Actual)
2024-01-08
Study Completion Date (Actual)
2026-05-19
Enrollment (Actual)
52
Study Type
Interventional
Phase
Phase 2